ELIAS JOSEPH JABBOUR to Farnesyltranstransferase
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Farnesyltranstransferase.
Connection Strength
0.599
-
Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs. 2007 Mar; 16(3):381-92.
Score: 0.283
-
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44.
Score: 0.091
-
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S272-9.
Score: 0.080
-
New agents in myelodysplastic syndromes. Curr Hematol Rep. 2005 May; 4(3):191-9.
Score: 0.062
-
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004 Nov; 45(11):2187-95.
Score: 0.060
-
Current and future management options for myelodysplastic syndromes. Drugs. 2010 Jul 30; 70(11):1381-94.
Score: 0.022